Arcline Investment Management is preparing to bring aerospace components maker Arxis to market in a $1.06bn US IPO, targeting a valuation of up to $11.2bn.

The offering will see 37.7m shares priced between $25 and $28 each, positioning the private equity-backed business among the largest defence-linked listings currently in the pipeline.

Moreover, the IPO reflects growing investor appetite for aerospace and defence assets, as geopolitical tensions drive demand for resilient, strategically important sectors. Recent filings from companies such as AEVEX and Elmet further highlight the trend towards defence-focused listings.

Arxis operates across electronic and mechanical components, serving aerospace, defence, medical technology, and specialised industrial markets. The company’s diversified exposure reinforces its positioning within mission-critical supply chains.

For Arcline, the IPO represents a key step towards monetising its investment, with proceeds set to be used primarily to reduce debt and support ongoing operations.

Strong institutional demand is already emerging. Capital International Investors, Capital Research Global Investors, Janus Henderson Investors, and T. Rowe Price have indicated interest in purchasing up to $400m in shares, signalling confidence in the offering.

Goldman Sachs, Morgan Stanley, and Jefferies are acting as joint bookrunners for the transaction, with Arxis expected to list on Nasdaq under the ticker “ARXS.”

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.